SillaJen, Inc.

KOSDAQ 215600.KQ

SillaJen, Inc. Cash and Short-Term Investments for the year ending December 31, 2023: USD 37.86 M

SillaJen, Inc. Cash and Short-Term Investments is USD 37.86 M for the year ending December 31, 2023, a -23.27% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • SillaJen, Inc. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 49.34 M, a -45.55% change year over year.
  • SillaJen, Inc. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 90.62 M, a 378.15% change year over year.
  • SillaJen, Inc. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 18.95 M, a -55.21% change year over year.
  • SillaJen, Inc. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 42.31 M, a -57.80% change year over year.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
SV Wall Street
KOSDAQ: 215600.KQ

SillaJen, Inc.

CEO Mr. Jaekyung Kim
IPO Date Dec. 6, 2016
Location South Korea
Headquarters O2 Tower
Employees 37
Sector Healthcare
Industries
Biotechnology Vaccines
Description

SillaJen, Inc. engages in the development and commercialization of oncolytic immunotherapy products. The company's lead product is Pexa-Vec, which is in Phase II clinical trial for the treatment of advanced liver cancer. It also develops JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. The company was founded in 2006 and is headquartered in Seoul, South Korea.

StockViz Staff

February 4, 2025

Any question? Send us an email